180 Life Sciences Corp.
ATNF
$1.95
$0.158.33%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -70.54% | -28.82% | -31.26% | 34.78% | 102.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -74.25% | -12.75% | -18.55% | 30.50% | 26.40% |
| Operating Income | 74.25% | 12.75% | 18.55% | -30.50% | -26.40% |
| Income Before Tax | 94.57% | 41.31% | -225.21% | -404.54% | -2,303.28% |
| Income Tax Expenses | 99.53% | -- | -- | -- | -14,183.33% |
| Earnings from Continuing Operations | 94.36% | 52.22% | -225.21% | -404.54% | -2,198.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 94.36% | 52.22% | -225.21% | -404.54% | -2,198.27% |
| EBIT | 74.25% | 12.75% | 18.55% | -30.50% | -26.40% |
| EBITDA | 74.48% | 13.38% | 18.52% | -30.85% | -26.03% |
| EPS Basic | 98.94% | 88.23% | -140.82% | -238.41% | -1,696.33% |
| Normalized Basic EPS | 94.20% | 66.56% | -140.82% | -238.40% | -444.68% |
| EPS Diluted | 98.94% | 88.23% | -140.90% | -238.41% | -1,723.02% |
| Normalized Diluted EPS | 94.20% | 66.56% | -140.82% | -238.44% | -444.68% |
| Average Basic Shares Outstanding | 430.58% | 305.92% | 206.57% | 120.09% | 31.47% |
| Average Diluted Shares Outstanding | 430.58% | 305.92% | 206.57% | 119.84% | 31.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
